Literature DB >> 25498859

Effects of donepezil on hERG potassium channels.

Yun Ju Chae1, Hong Joon Lee2, Ji Hyun Jeon3, In-Beom Kim3, Jin-Sung Choi4, Ki-Wug Sung2, Sang June Hahn5.   

Abstract

Donepezil is a potent, selective inhibitor of acetylcholinesterase, which is used for the treatment of Alzheimer's disease. Whole-cell patch-clamp technique and Western blot analyses were used to study the effects of donepezil on the human ether-a-go-go-related gene (hERG) channel. Donepezil inhibited the tail current of the hERG in a concentration-dependent manner with an IC50 of 1.3 μM. The metabolites of donepezil, 6-ODD and 5-ODD, inhibited the hERG currents in a similar concentration-dependent manner; the IC50 values were 1.0 and 1.5 μM, respectively. A fast drug perfusion system demonstrated that donepezil interacted with both the open and inactivated states of the hERG. A fast application of donepezil during the tail currents inhibited the open state of the hERG in a concentration-dependent manner with an IC50 of 2.7 μM. Kinetic analysis of donepezil in an open state of the hERG yielded blocking and unblocking rate constants of 0.54 µM(-1)s(-1) and 1.82 s(-1), respectively. The block of the hERG by donepezil was voltage-dependent with a steep increase across the voltage range of channel activation. Donepezil caused a reduction in the hERG channel protein trafficking to the plasma membrane at low concentration, but decreased the channel protein expression at higher concentrations. These results suggest that donepezil inhibited the hERG at a supratherapeutic concentration, and that it did so by preferentially binding to the activated (open and/or inactivated) states of the channels and by inhibiting the trafficking and expression of the hERG channel protein in the plasma membrane.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer׳s disease; Channel trafficking; Donepezil; hERG

Mesh:

Substances:

Year:  2014        PMID: 25498859     DOI: 10.1016/j.brainres.2014.11.057

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Inhibition of cloned hERG potassium channels by risperidone and paliperidone.

Authors:  Hong Joon Lee; Jin-Sung Choi; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-03-06       Impact factor: 3.000

Review 2.  Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.

Authors:  J R Giudicessi; M J Ackerman; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-14       Impact factor: 3.598

Review 3.  Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels.

Authors:  Xian-Tao Li
Journal:  Metab Brain Dis       Date:  2022-01-31       Impact factor: 3.584

4.  QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine.

Authors:  Katie Malone; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

5.  Inhibitory effects of cholinesterase inhibitor donepezil on the Kv1.5 potassium channel.

Authors:  Kai Li; Neng Cheng; Xian-Tao Li
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 6.  Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.

Authors:  Yichang Huang; Mhd Wasem Alsabbagh
Journal:  Pharmacol Res Perspect       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.